Moderna, Inc. (NASDAQ:MRNA) is a leading biotechnology company renowned for its mRNA technology, which has been crucial in developing COVID-19 vaccines. Competing against pharmaceutical giants like Pfizer and BioNTech, Moderna has made significant strides in the industry. On January 19, 2026, Citigroup updated its rating for Moderna to "Neutral," suggesting investors hold onto the stock. At this time, the stock was trading around $41.84.
Investors often target stocks poised to surpass quarterly earnings estimates, as these can significantly impact stock prices. According to Zacks Investment Research, earnings and interest rates are pivotal in determining stock prices over the long term. While investors cannot control interest rates, earnings surprises can trigger notable stock price movements.
The Zacks Earnings ESP (Expected Surprise Prediction) tool is designed to identify potential earnings surprises by examining recent analyst revisions. Adjustments in earnings estimates prior to an earnings release may signal an impending earnings surprise. Utilizing these insights, investors can potentially improve their investment returns.
Currently, Moderna's stock is valued at $41.84, marking a 6.29% increase. The stock has experienced a rise of $2.48 today, with trading fluctuations ranging between $40.55 and $42.30 throughout the day. Over the past year, the stock has achieved a high of $45.40 and a low of $22.28, with a market capitalization of approximately $16.35 billion. The trading volume for the day is reported at 11,891,053 shares on the NASDAQ exchange.
